Search results for "Infliximab"
showing 10 items of 98 documents
Splenic tuberculosis in a patient with Crohn's disease on infliximab: Case report
2010
Infliximab prevents Crohn's disease recurrence after ileal resection.
2009
Infliximab to treat Crohn's disease: an update
2011
Abstract: Crohn’s disease (CD) is a chronic inflammatory disease of the gastrointestinal tract characterized by recurring flares followed by periods of inactive disease and remission. The etiology is unknown, although the common opinion is that the disease arises from a disordered immune response to the gut contents in genetically predisposed individuals. Infliximab (IFX), a chimeric immunoglobulin G1 monoclonal antibody to tumor necrosis factor, has dramatically changed the approach to managing patients with CD and improving their treatment, by achieving treatment goals, such as mucosal healing, and decreasing the need for hospitalizations and surgeries. This review provides an update on e…
SP0027 Biosimilars: Potential Clinical Differences and European Regulatory Aspects
2014
Although successful drugs, the use of anti-TNFs is limited by their high cost, and in the present climate of economic difficulty, there is pressure to find alternatives that reproduce their effects at a lower price. Due to their large molecular size and structural complexity, anti-TNFs are impossible to duplicate, unlike smaller, chemically-generated compounds, which can be copied. However, unlike generics, biosimilars are similar rather than identical to the original drugs. Determining the level of similarity that guarantees a comparable efficacy and safety represents a new test for the pharmacological market. Biosimilars of smaller biological molecules, such as somatotropin, EPO and GCSF …
797 Infliximab in the Treatment of Pediatric Ibd: A Single Centre Experience
2010
Background and aims: The biological treatment of IBD acts on different stages of immunophysiopathological processes of the disease. We describe evolution and clinical response to Infliximab in paediatric patients affected by IBD diagnosed and followed at our centre. Methods: In the last triennial period at our Department of Paediatrics in Palermo 53 infusions of Infliximab were administrated to our patients affected by severe forms of IBD. All patients but one were affected by several forms of CD. Only one child was affected by U.C. associated to pyoderma gangrenosum. The total number of infusions were administrated according the ACCENT 1 study at a dose of 5 mg/Kg. All the infusions were p…
Infections sévères à pyogènes chez les patients traités par infliximab. Étude d’une cohorte régionale
2005
Resume Objectif. – Apprecier la prevalence des infections severes a pyogenes chez les patients traites par infliximab en pratique courante, et essayer de degager des facteurs favorisants. Methodes. – Etude portant sur une cohorte de patients traites dans un reseau regional par infliximab pour polyarthrite rhumatoide ou spondylarthrite ankylosante, et suivis de facon prospective a l’aide d’une feuille de recueil des donnees standardisee. Les observations des patients ayant presente une infection grave a pyogene ont ete analysees, et comparees a celles des autres patients. Resultats. – La cohorte comportait 83 patients (55 femmes et 28 hommes), dont cinq (6 %) ont presente une infection sever…
AB0438 Safety of tnf blockers in case of non-alcoholic fatty liver disease and cirrhosisa systematic review
2018
Background The management of inflammatory rheumatisms and psoriasis has largely evolved over the last 15 years with the emergence of biotherapies whose main adverse effect is the increased infection risk. The prevalence of metabolic syndrome is increasing and has been estimated at 30% in patients with rheumatoid arthritis with an excess of 45% compared to healthy subjects. One of the major complications of the metabolic syndrome is the Non Alcoholic Fatty Liver Disease (NAFLD), which prevalence is 25% in the global population, and 30% in a cohort of patients with rheumatoid arthritis. The main complication of NAFLD is the development of cirrhosis, known to increase infectious risk. Surprisi…